(Total Views: 341)
Posted On: 03/10/2020 12:44:35 PM
Post# of 36566
Thomas, where did the share count numbers come from?
"Which brings us to Generex, and we begin again with NGIO, which started life with 150 million shares; about another 20 million were added with the recently paid stock dividend, so that would be 170 million shares. Perhaps another 10 million will be added with the IPO. As a point of reference, INO which announced human trials beginning in April, has seen its market cap increase by a staggering $1 billion in the last 9 days to $1.4 billion. If NGIO were to have a vaccine in hand before their planned IPO, I think the pricing would be in the $7-$9 range. Without it, probably more in the $2 to $4 range."
"Which brings us to Generex, and we begin again with NGIO, which started life with 150 million shares; about another 20 million were added with the recently paid stock dividend, so that would be 170 million shares. Perhaps another 10 million will be added with the IPO. As a point of reference, INO which announced human trials beginning in April, has seen its market cap increase by a staggering $1 billion in the last 9 days to $1.4 billion. If NGIO were to have a vaccine in hand before their planned IPO, I think the pricing would be in the $7-$9 range. Without it, probably more in the $2 to $4 range."
(1)
(0)
